Log in

NASDAQ:IMVTImmunovant Stock Price, Forecast & News

$14.20
-1.01 (-6.64 %)
(As of 04/5/2020 01:42 PM ET)
Add
Compare
Today's Range
$13.86
Now: $14.20
$15.63
50-Day Range
$8.36
MA: $14.28
$17.04
52-Week Range
$8.34
Now: $14.20
$18.69
Volume137,660 shs
Average Volume193,428 shs
Market Capitalization$772.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody targeting the neonatal Fc receptor, which is in phase II clinical trial for the treatment of myasthenia gravis and graves' ophthalmopathy. The company was formerly known as Health Sciences Acquisitions Corporation and changed its name to Immunovant, Inc. in December 2019. Immunovant, Inc. was incorporated in 2018 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.83 out of 5 stars


Industry, Sector and Symbol

Industry Holding & other investment offices
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMVT
CUSIPN/A
CIKN/A
Phone917-580-3099

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees17
Market Cap$772.48 million
Next Earnings Date5/8/2020 (Estimated)
OptionableNot Optionable

Receive IMVT News and Ratings via Email

Sign-up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.


Immunovant (NASDAQ:IMVT) Frequently Asked Questions

How has Immunovant's stock been impacted by COVID-19 (Coronavirus)?

Immunovant's stock was trading at $14.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IMVT stock has increased by 0.4% and is now trading at $14.20. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Immunovant?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Immunovant.

When is Immunovant's next earnings date?

Immunovant is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Immunovant.

How were Immunovant's earnings last quarter?

Immunovant (NASDAQ:IMVT) released its quarterly earnings results on Friday, February, 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.03. View Immunovant's earnings history.

What price target have analysts set for IMVT?

5 brokers have issued 1 year target prices for Immunovant's stock. Their forecasts range from $21.00 to $30.00. On average, they anticipate Immunovant's stock price to reach $25.20 in the next year. This suggests a possible upside of 77.5% from the stock's current price. View analysts' price targets for Immunovant.

Has Immunovant been receiving favorable news coverage?

News headlines about IMVT stock have trended very negative recently, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immunovant earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutImmunovant.

Are investors shorting Immunovant?

Immunovant saw a increase in short interest in March. As of March 13th, there was short interest totaling 813,900 shares, an increase of 8.8% from the February 27th total of 747,900 shares. Based on an average daily volume of 110,800 shares, the short-interest ratio is currently 7.3 days. Approximately 16.7% of the shares of the company are short sold. View Immunovant's Current Options Chain.

Who are some of Immunovant's key competitors?

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Repligen (RGEN), Paypal (PYPL), PPD (PPD), Progyny (PGNY), Passage Bio (PASG), InMode (INMD), INmune Bio (INMB), Interpace Diagnostics Group (IDXG), Cabaletta Bio (CABA) and I-Mab (BDTX).

Who are Immunovant's key executives?

Immunovant's management team includes the following people:
  • Dr. Peter Salzmann M.B.A., M.D., CEO & Director
  • Ms. Pamela Yanchik Connealy M.B.A., Chief Financial Officer
  • Dr. Sandeep C. Kulkarni, Chief Operating Officer
  • Dr. Julia G. Butchko Ph.D., Chief Devel. & Technology Officer
  • Mr. W. Bradford Middlekauff, Gen. Counsel (Age 58)

What is Immunovant's stock symbol?

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

How do I buy shares of Immunovant?

Shares of IMVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immunovant's stock price today?

One share of IMVT stock can currently be purchased for approximately $14.20.

How big of a company is Immunovant?

Immunovant has a market capitalization of $772.48 million. Immunovant employs 17 workers across the globe. View additional information about Immunovant.

What is Immunovant's official website?

The official website for Immunovant is http://www.immunovant.com/.

How can I contact Immunovant?

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK 10, 10018. The company can be reached via phone at 917-580-3099.

This page was last updated on 4/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel